AnaptysBio. has filed a patent for anti-TIM-3 antibodies with specific sequences to treat diseases like cancer, infectious diseases, and autoimmune diseases. The claim mentions canceled claims 1-14. GlobalData’s report on AnaptysBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AnaptysBio Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AnaptysBio, Personalized cancer vaccines was a key innovation area identified from patents. AnaptysBio's grant share as of January 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-tim-3 antibodies for treating diseases

Source: United States Patent and Trademark Office (USPTO). Credit: AnaptysBio Inc

The patent application (Publication Number: US20230416368A1) discloses an antibody agent designed for treating disorders responsive to TIM-3 inhibition, particularly cancer. The antibody agent comprises a heavy chain polypeptide and a light chain polypeptide with specific amino acid sequences. The patent claims cover the antibody agent binding to TEVI-3 within a specific range of KD values and its use in compositions with pharmaceutically acceptable carriers.

Furthermore, the patent application outlines a method for treating TIM-3 responsive disorders, specifically cancer, by administering the antibody agent to mammals, including humans. The method also involves combining the antibody agent with an agent that inhibits Programmed Cell Death 1 (PD-1), such as nivolumab, pembrolizumab, or TSR-042. The patent also covers the manufacturing process of the antibody agent through nucleic acid expression in host cell culture, emphasizing the importance of specific sequence identities in the heavy and light chain polypeptides for optimal efficacy in treating various cancers.

To know more about GlobalData’s detailed insights on AnaptysBio, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies